A patient at Abu Dhabi’s Sheikh Shakhbout Medical City (SSMC) has been effectively treated for a severe thyroid eye disease (TED) using a newly FDA-approved medication. The treatment, Teprotumumab-trbw, addresses the root cause of TED and not just its symptoms, offering hope for those suffering from this autoimmune condition. After experiencing issues like blurry vision, eye pain, and redness, the patient sought help from SSMC’s experts, who diagnosed him with severe TED and offered this groundbreaking treatment. Teprotumumab-trbw, a monoclonal antibody therapy, reduces inflammation and improves symptoms like pain, swelling, double vision, and bulging eyes. The patient’s remarkable recovery highlights the potential of this new medication to transform the lives of TED patients and prevent irreversible eye damage.